Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:54 PM
Ignite Modification Date:
2025-12-24 @ 6:54 PM
NCT ID:
NCT00718757
Eligibility Criteria:
Inclusion Criteria:
* Age \< or equal to 21 years at time of study entry
* Pathological diagnosis of a recurrent or refractory Non-Hodgkin's lymphoma, Hodgkin's disease, or acute lymphoblastic leukemia
* ECOG performance status \< or equal to 2 (or Lansky play-performance scale \> or equal to 50% for children \<10 years of age).
* Has not received chemotherapy in previous 2 weeks. In the case of rapidly progressing disease, this criterion may be waived by consulting with the Principal Investigator, provided the patient has recovered from the acute effects of prior therapy.
* Hemoglobin \>8 g/dl, absolute neutrophil count \>1000 /mm3 (without growth factor support), and platelet count \>50,000/mm3 (without transfusion support) unless bone marrow is involved with tumor or leukemia
* Adequate liver function (bilirubin \< 1.5 x normal for age, AST and ALT \< 3 x normal for age)
* Adequate renal function (serum creatinine \<3 x normal for age)
* No active graft-versus-host disease (GVHD) or ongoing treatment for GVHD
Exclusion Criteria:
* Currently receiving other cytotoxic or investigational drugs
* Pregnant or lactating females are not eligible. Pregnancy tests must be obtained in females who are post-menarchal.
* Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, azole antifungals, aprepitant, or St. John's Wort is not allowed.
* Evidence of active infection at the time of protocol entry
* History of allergy to any of the study medications
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
21 Years
Study:
NCT00718757
Study Brief:
Protocol Section:
NCT00718757